^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Solucin (177Lu-edotreotide)

    i
    Other names: 177Lu-DOTATOC, ITM-11, n.c.a. 177Lu-edotreotide, 177Lu-Edo, ITM11, ITM 11
    Associations

    News

    Trials
    Company:
    China Grand Pharma, ITM Isotopen Technologien Munchen
    Drug class:
    Beta radiation emitter, SSTR2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Recruiting, ITM Solucin GmbH | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Solucin (177Lu-edotreotide)
    1m
    Systematic review and meta-analysis of the efficacy and safety of [177Lu]Lu-edotreotide ([177Lu]Lu-DOTATOC) for the treatment of neuroendocrine tumors. (PubMed, J Neuroendocrinol)
    Overall, these findings suggest that the efficacy and safety of [177Lu]Lu-edotreotide are in line with those reported for other RPTs in similar clinical settings. Clinical Trial Registration: PROSPERO 2024 CRD42024518028.
    Retrospective data • Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    Solucin (177Lu-edotreotide)
    3ms
    START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
    P3, N=300, Recruiting, Lund University Hospital | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    capecitabine • Solucin (177Lu-edotreotide)
    7ms
    Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE (clinicaltrials.gov)
    P3, N=259, Active, not recruiting, ITM Solucin GmbH | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    SSTR (Somatostatin Receptor)
    |
    SSTR positive
    |
    5-fluorouracil • everolimus • temozolomide • capecitabine • oxaliplatin • leucovorin calcium • Solucin (177Lu-edotreotide)
    8ms
    PROMENADE: Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide (clinicaltrials.gov)
    P1/2, N=18, Recruiting, University Hospital, Basel, Switzerland | Phase classification: P1 --> P1/2 | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Phase classification • Trial completion date • Trial primary completion date
    |
    SSTR (Somatostatin Receptor)
    |
    SOMther (lutetium-177 DOTA satoreotide) • Solucin (177Lu-edotreotide)
    9ms
    A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217). (PubMed, BMC Cancer)
    The LEVEL trial will investigate if 177Lu-edotreotide has the potential to be incorporated as a standard treatment option for patients with NETs from the lung and Thymus.
    Clinical • Clinical protocol • Journal • HEOR
    |
    SSTR (Somatostatin Receptor) • SSTR2 (Somatostatin Receptor 2)
    |
    everolimus • Solucin (177Lu-edotreotide)
    1year
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Sep 2024 --> Jan 2025
    Trial initiation date
    |
    Solucin (177Lu-edotreotide)
    1year
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ITM Solucin GmbH | Initiation date: Jun 2024 --> Sep 2024
    Trial initiation date
    |
    Solucin (177Lu-edotreotide)
    over1year
    START-NET: Systemic Targeted Adaptive RadioTherapy of NeuroEndocrine Tumors. (clinicaltrials.gov)
    P3, N=300, Recruiting, Lund University Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    SSTR (Somatostatin Receptor)
    |
    capecitabine • Solucin (177Lu-edotreotide)
    over1year
    LUFOR: "Receptor Radionuclide Therapy With 177Lu-DOTATOC (clinicaltrials.gov)
    P2, N=100, Recruiting, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | Not yet recruiting --> Recruiting
    Enrollment open
    |
    SSTR2 (Somatostatin Receptor 2)
    |
    Solucin (177Lu-edotreotide)
    over1year
    177Lu-labeled somatostatin receptor targeted radionuclide therapy dosimetry in meningioma: a systematic review. (PubMed, Q J Nucl Med Mol Imaging)
    The tumor AD that was reported during treatment with 177Lu-SSTR-RT in refractory meningioma patients is generally low. Harmonization of the methodology for dosimetry calculations is needed to compare the different reported values and optimize treatment at the individual level.
    Review • Journal
    |
    SSTR (Somatostatin Receptor)
    |
    Lutathera (lutetium Lu 177 dotatate) • Solucin (177Lu-edotreotide)
    over1year
    KinLET: Phase I Trial to Determine the Dose and Evaluate the PK of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, ITM Solucin GmbH
    New P1 trial
    |
    Solucin (177Lu-edotreotide)